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Background and objective: Growth of beneficial probiotics is attributed to their tolerance to 
stress factors while most probiotics have a relatively short and unstable shelf life. Bacillus 
coagulans, an economically important spore-forming species, is becoming increasingly 
remarkable in field of probiotics for the decrease of harmful effects of processing and 
environment conditions on the survival of bacterial cells and to assure their functionality in 
the human body. The aim of this review was to explore scientific research on therapeutic, 
functional and biosafety properties of Bacillus coagulans as a novel probiotic. 
Results and conclusion: Many scientific literatures have been published on the use of health 
promoting Bacillus spores in foods. Bacillus coagulans mostly includes several health benefits 
of non-spore forming probiotics and is able to tolerate heat and stressful requirements of food 
processing as well as gastrointestinal tract conditions. Considering specific characteristics of 
spore-forming probiotics, Bacillus coagulans demonstrates a promising potential in produc-
tion of probiotic foods. 
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Probiotics are available in various forms of functional 
foods and dietary supplements for human use. Dairy 
products are the most commonly sold carriers of probiotic 
bacteria. Furthermore, capsules and tablets containing 
lyophilized probiotic bacteria are available in health food 
stores [1]. E-commerce platforms provide medications, 
which can be used to treat gastrointestinal tract (GIT) 
diseases. Many of these products contain lactobacilli and 
bifidobacteria as key members of probiotic group [2]. A 
large number of scientific reports have focused on these 
probiotic species, investigating various aspects such as 
industrial applications, therapeutic properties and 
biosafeties [1,3]. Lactobacilli and bifidobacteria are 
sensitive to physiological conditions such as pH of the 
stomach and bile salts. Moreover, bioavailability of these 
bacteria is affected by various conditions of production, 
storage and transportation [4,5]. Use of spore-forming 
bacteria includes advantages compared to that use of 
lactobacilli does because products containing these 
bacteria can be preserved in dry forms at room temperature 
without any negative effects on the survival of spores. 
Another advantage of using spores is linked to their ability 
to tolerate low pH and successfully passing the GIT. 
Bacterial spores include a greater resistance to thermal 
lethal effects, drying, freezing, toxic chemicals and 
radiation compared to that vegetative cells do [6,7]. 
In recent years, a number of Bacillus spp. have been 
reported as novel probiotics [8]. Spore-forming bacilli 
have been used for many years for food production and 
preservation. The importance of bacilli bacteria in food 
chains is associated to their innate production of an 
extensive number of enzymes, vitamins, antimicrobials and 
protein compounds as well as organic pigments such as 
carotenoids. In fact, Bacillus spp. become popular in 
human health and functional food research primarily due to 
their enhanced tolerance and survivability under the 
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antagonistic environment of GIT [9,10]. Furthermore, 
stability of Bacillus microflora during food processing and 
storage makes them ideally functional candidates for health 
boosting formulations [7]. A challenge currently exists as 
most probiotic products failed to receive much credentials 
in public view despite of their scientific advancements and 
evidence that show effectiveness of commercial probiotic 
supplements and functional foods containing Bacillus 
species. One of the important reasons for this is linked to 
ongoing controversy between the probiotic and pathogenic 
aspects of Bacillus spp. Therefore, the current review 
aimed to provide up-to-date scientific information on 
Bacillus species as spore-forming probiotics, particularly 
Bacillus (B.) coagulans. 
2. Spore-forming bacillus as probiotics 
Use of Bacillus species in food products has been 
documented for more than 50 years. This species was 
introduced to European markets as Enterogermina
®
; first 
introduced and registered in Italy as a medicinal 
supplement in 1958 [4,11]. Traditional use of spore-
forming bacteria that produce lactic acid (LA) has been 
documented as well [12,13]. The most comprehensively 
investigated species of spore-forming Bacillus include B. 
licheniformis, B. clausii, B. coagulans, B. cereus and B. 
subtilis [14]. Although the most common probiotic species 
are those producing LA (Lactobacillus spp.), no universal 
classes of probiotics exist currently. These bacteria are 
found normally in GIT of humans and animals; however, 
obscure reports show that use of indigenous 
microorganisms somehow restitutes the natural microflora 
of GIT [15,16]. The second class of probiotics includes 
those not normally found in GIT. A member of this group 
of probiotics is Bacillus genus, which typically produces 
spores to survive harsh environmental conditions such as 
heat, drought, freezing, radiation and rising oxygen levels 
[17,18]. Relatively, material coating and encapsulation are 
suggested to enhance the survival of probiotics exposed to 
simulated GIT conditions [19]. Most recently, certified 
spore-forming Bacillus spp. are used in dry probiotic 
products, meaning that they can be stored indefinitely on 
the shelf [20,21]. However, use of products containing 
spore-forming bacteria raises a number of questions. One 
of these questions mainly includes the fact that since 
germination, proliferation and resporulation (when food is 
restricted) comprise of the spore life cycle, how Bacillus 
probiotics exert beneficial effects within such a life cycle? 
Based on the suggested performance models for probiotic 
bacteria, probiotics demonstrate functionalities of live 
bacteria within the GIT [12]. 
Based on the medical importance of probiotic 
microorganisms, food and drug producers are interested in 
formulating products with novel and further resistant 
probiotic strains [22]. Bacterial endospore structures 
include a condensed inactive chromosome and extra layers 
such as a peptidoglycan-rich cortex and proteinaceous 
materials. These structures preserve bacteria in harsh 
conditions such as those in GIT [23-25]. A specified dose 
of Bacillus spores can be stored indefinitely outside of 
refrigerators and almost an entire dose of the intake 
bacteria reaches the small intestine intact. Rapidly after 
exposure to nutrients and moistures, spores shift from 
inactive form to vegetative form [26-28]. Spores can 
survive in industrial conditions and hence provide long-
term survivals of the bacteria [29]. However, it is 
important to provide appropriate conditions such as heat 
shock and optimized culture media for the activation and 
recovery of spores to assess the probiotic viability during 
shelf life or exposure to GIT conditions [30-32]. A limited 
number of spore-forming bacilli are considered as 
probiotics in following food categories of dairy products, 
baked goods, fruit juices, confections, grain products, 
pastas, beverages, chewing gums, breakfast cereals, hard 
candies, seasonings, nut products, processed vegetables, 
coffees, teas, blends, extracts, flavorings and several other 
wet and dry food products [33]. 
3. Bacillus coagulans in health foods 
and dietary supplements 
Nowadays, many Bacillus products are sold online as 
novel foods and dietary supplements with claimed health 
benefits such as restoring the natural microflora of the 
GIT. However, some of these products carry poorly 
defined or invalid probiotic species [6,12]. Of hundreds of 
known Bacillus spp., only B. coagulans (Figure 1) and B. 
subtilis var. natto have generally been accepted as 
admissible probiotics for human consumption. Natto is a 
Japanese food product made by fermenting cooked 
soybeans with B. subtilis var. natto. This food product has 
been proven to include probiotic attributes since B. subtilis 
var. natto is believed to stimulate the immune system, pose 
anti-cancer properties and produce vitamin K2 [34-37]. The 
wide use of Natto in Japan and public belief in its 
beneficial and functional properties seem to support the 
concept of probiotics. To date, a number of B. coagulans 
strains are described as probiotics (Table 1) and used in 
production of food products and dietary supplements 
(Table 2). In a recent report, B. coagulans GBI-30, 6086 
was described as an aid for the absorption and utilization 
of proteins. The bacteria can tolerate acidic conditions of 
the stomach to arrive in the intestine (where it can 
germinate), and subsequently help in digestion of 
carbohydrates and proteins. Consumption of B. coagulans 
GBI-30, 6086 with proteins has been demonstrated to 
increase protein absorption, boosting efficiency of dietary 
protein supplementation. Therefore, health improvement 
of muscles in different populations and reduced quality 
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differences between proteins from different sources (e.g. 
plant proteins) are resulted from B. coagulans GBI-30, 
6086 consumption [38,39]. B. coagulans MTCC 5856 has 
been studied in functional foods to show its stability during 
processing and storage. A number of functional food 
products with various nutritional profiles (e.g. banana 
muffins, waffles, chocolate fudge frostings, peanut butters, 
fruit preserves and vegetable oils) have been studied to 
investigate the stability of B. coagulans MTCC 5856. The 
bacteria was reportedly stable during baking, brewing, 
refrigerating and freezing of the highlighted functional 









Table 1. Various probiotic strains of Bacillus coagulans 
Bacteria Reference 
B. coagulans GBI-30, 6086 [38] 
B. coagulans MTCC 5856 [33] 
B. coagulans Unique IS-2 (MTCC 5260) [49] 
B. coagulans S-lac [65] 
B. coagulans 2-6 [65] 
B. coagulans CSIL1 [65] 
B. coagulans 36D1 [66] 
B. coagulans HM-06 [65] 
B. coagulans H1 [65] 
B. coagulans HM-08 [67] 
B. coagulans= Bacillus coagulans 
 
 
Table 2. Examples of probiotic food products and nutritional supplements containing B. coagulans available in global 
markets 
Product brand Product type Country 
THRONE NS* United States 
Harvest Soul  Fruit and vegetable juices United States 
Nature’s Bounty Gummies 
Dark chocolate 
United States 
Solaray NS United States 
Nature Made Gummies United States 
Attune Dark chocolate United States 
Linwoods Ground flaxseed United States 
Purely Elizabeth Chocolate sea salt United States 
Udi’s Granola bar United States 
Bigelow Lemon ginger tea United States 
Megasporebiotic NS United Kingdom 
Betty Lou’s Dark chocolate United States 
COOPER MOON Cappuccino United States 
ProDURA NS United States 
Happy Yo ProTM Yogurt United States 
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4. Bacillus species in therapeutic 
products 
Potential advantages of Bacillus species include 
improved nutritional values and growth, boosted immunity 
levels and prevented GIT diseases such as diarrhea, 
irritable bowel syndrome (IBS) and inflammatory bowel 
disease, ulcerative skin disorders, bacterial vaginoses and 
cancers [40]. These originally soil based organisms exhibit 
typical characteristics of Lactobacillus and Bacillus genera. 
They are spore-forming (terminal spore), Gram positive, 
catalase-positive, metabolically thermotolerant, rod-
shaped, facultative anaerobes, which produce only L-lactic 
acid but do not produce gas from the fermentation of 
various sugars such as maltose, mannitol, raffinose, 
sucrose and trehalose. B. coagulans was first isolated from 
spoiled milk in 1915 when an outbreak of flat-sours 
(coagulation) occurred in evaporated milk packed by an 
Iowa condenser and wrongly classified as a L. sporogenes 
[41,42]. This microorganism was reclassified in Bergey's 
Manual of Determinative Bacteriology as B. sporogenes 
since 1957. According to 8
th
 edition of this book, B. 
sporogenes shares the same characteristics of B. coagulans 
and has therefore been re-categorized in B. coagulans 
group. Terminal position of the endospore in cells, lack of 
cytochrome C oxidase and inability to reduce nitrate to 
nitrite discriminate these bacteria from other bacteria 
within Bacillus genus. 
Based on the Patent Cooperation Treaty, Kibow 
Biotech Inc. is developing B. coagulans for curing GIT 
infections. The bacterial therapeutic effect is due to 
coagulin (the bacteriocin secreted from B. coagulans), 
which includes activities against extended-spectrums of 
enteric microbes [43]. Documented evidence have 
demonstrated useful effects of Bacillus probiotics on 
urinary tract infections. Bacillus probiotics cause a 
significant depletion in frequency of urinary tract 
infections episodes in patients treated with Bacillus spores 
and antibiotics [44]. Manipur Ngari is a fermented fish 
food that is made by B. coagulans BDU3B. This strain 
produces a novel bacteriocin that shows antimicrobial 
activities against a wide range of pathogenic 
microorganisms. This bacteriocin, which is the smallest 
bacteriocin isolated from B. coagulans, can be used as a 
bio-preservative in foods [45]. B. coagulans is considered 
as an economically significant species based on a spore-
like protein coat that protects the bacteria from acidic 
conditions of the stomach [46]. This Bacillus produces 
optically pure LA [47], coagulin and thermostable 
enzymes [46]. The optimum temperature and pH for the 
growth of these bacteria include 35-50°C and 5.5-6.5, 
respectively. Studies have shown that the presence of 
diluted HCL or NaOH solutions promotes germination of 
spores [30,48]. A recent study has investigated in vitro 
anti-proliferative effects of B. coagulans Unique IS2 on 
three types of cancers, including human colon cancer, 
cervical cancer and chronic myeloid leukemia. A human 
embryonic kidney cell line was used as noncancerous 
control. Results have shown that the heat-killed culture 
supernatant of this strain is effective in induction of 
programmed cell death (apoptosis) of the colon cancer. 
This can be considered for adjuvant therapy in treatment of 
colon carcinoma [49]. Bacillus probiotics are developed 
for topical and oral treatments of uremia. This bacterial 
genus is able to produce antimicrobial compounds and 
small effector molecules that interact with the host milieu, 
resulting in bacterial biotherapeutic potentials [7].  
5. In vivo and human studies on 
Bacillus coagulans as a probiotic 
Published scientific reports have described significant 
roles of B. coagulans as a novel probiotic in hosts (humans 
and animals), compared to existing documented uses of 
probiotic Lactobacillus spp. [7,50]. As discussed earlier, B. 
coagulans is used as a probiotic in liquid food products 
with low water activities (aw). Following oral 
administration, spores of B. coagulans pass through the 
stomach and, upon arrival in the first part of the intestine 
(duodenum), germination and multiplication occurs rapidly 
[26,48]. Assessments suggest that the average time 
between oral dosing and germination includes four hours 
[48,51]. Germinated B. coagulans cells produce LA once 
they become metabolically active as a part of the 
facultative anaerobes in small intestine and colon. These 
cells are slowly excreted through feces over approximately 
seven days after discontinuation of consumption [52,53]. 
B. coagulans has been asserted to improve GIT ecology by 
restoring the quantity of favorable obligatory bacteria and 
antagonizing pathogenic microorganism [33]. Effects of B. 
coagulans Unique IS2 on serum cholesterol levels were 
investigated in hypercholesterolemic patients. At the end 
of the studies, total cholesterol and LDL were slightly 
decreased, while HDL cholesterol was increased. 
Furthermore, no adverse effects of B. coagulans Unique 
IS2 administration were observed [54,55]. In another 
study, effects of oral supplementation of B. coagulans 
Unique IS2 were assessed in subjects with bacterial 
vaginosis. Forty Indian women suffering from bacterial 
vaginosis were participated in this study. Participants 
received probiotic treatments in three major groups. 
Results from the study showed an 80% reduction in 
vaginosis symptoms in patients treated with the probiotics, 
compared to the control group [56]. Sudha et al. 
investigated effects and safety of B. coagulans Unique IS2 
in treatment of acute diarrhea [57]. A total of 28 patients 
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(at various ages) suffering from acute diarrhea were 
participated in a clinical trial. All participants received 
capsules containing at least 2 × 10
9
 CFU of B. coagulans 
Unique IS2 two times a day for ten days. Efficacy was 
assessed by recording the duration of diarrhea, frequency 
of defecation, consistency of feces and abdominal pain. 
Results of therapy with B. coagulans Unique IS2 
demonstrated decreases in abdominal pain, duration of 
diarrhea and frequency of defecation. 
Effects of oral consumption of two spore-forming 
probiotics on population of fecal coliforms and other gut 
microbiota have been investigated in rat models. Totally, 
36 adult male albino rats were divided into four major 
groups of nine members and used in an experiment for 49 
days with seven days of adaptation. Group 1 was fed on a 
basal diet in addition to sterile skim milk for 28 days. 
Groups 2 and 3 received the basal diet and skim milk 
inoculated with at least 8 log CFU ml
-1
 of B. coagulans 
B37 and B. pumilus B9 spores, respectively. The control 
group was fed with the basal diet and clean water. Fecal 
sampling was carried out at 7-day intervals and 
enumerated for Bacillus spores, coliforms and lactobacilli. 
Fecal coliform counts decreased but Bacillus spores and 
lactobacilli counts increased in rats fed with either B. 
pumilus or B. coagulans B37, compared to control group. 
This study showed that oral administration of B. coagulans 
B37 and B. pumilus B9 strains might be useful in control 
of coliform bacteria and in increase of lactobacilli counts 
in intestinal microflora of rats [58]. Patients who suffer 
from IBS are mostly unsatisfied with current medications. 
Probiotics may alleviate this lifelong disease and relieve its 
unfavorable symptoms. In 2009, a study was carried out to 
investigate possible effects of B. coagulans GBI-30, 6086 
on IBS symptoms. Totally, 44 patients participating in that 
clinical trial study received placebo and B. coagulans GBI-
30, 6086 every day for eight weeks and the severity of IBS 
symptoms was recorded. Improvements from baseline 
symptom scores in probiotic group were statistically 
significant for all comparisons during the study. Changes 
in abdominal pain scores at Weeks 6 and 8 showed 
statistical significance in the placebo group. Due to no 
treatment-linked adverse effects during the study, primitive 
results suggested that this spore-forming probiotic might 
be a safe and impressive choice for the reduction of 
symptoms in patients with IBS [59]. 
Generally, decreased benefits of probiotic bacteria (e.g. 
Bifidobacterium spp.) and aspects of inherent immune 
functions are linked to advanced life age. Nyangale et al. 
investigated possible effects of daily oral administration of 
a spore-forming probiotic [B. coagulans GBI-30, 6086 
(BC30); GanedenBC30] on improving immune and gut 
functions in elderly men and women aged 65-80 years 
[60]. A total number of 36 participants were randomly 
assigned to receive a microcrystalline cellulose capsule 
(placebo) or a capsule containing 1 × 10
9
 CFU of BC30 
probiotic (placebo or probiotic) a day for 28 days, followed 
by 21 days of washout before shifting to other treatments. 
Blood and fecal samples were collected before and after 
each treatment and bacteria were enumerated in the fecal 
samples. Populations of Faecalibacterium prausnitzii 
significantly increased by consumption of BC30, compared 
to consumption of the placebo. Populations of Bacillus 




 from the 
baseline in probiotic group. Results of the study indicated 
that daily consumption of BC30 by elderly adults could 
increase populations of beneficial bacteria in human gut 
and potentially increases production of anti-inflammatory 
cytokines. 
6. Safety assessment of Bacillus 
coagulans as a spore-forming probiotic  
Strains of B. coagulans can survive in harsh conditions 
(heat, stomach acid and bile salts); to which, generally 
consumed probiotics are sensitive. Although strains of B. 
coagulans have widely been consumed around the world 
for decades, a few studies on toxicology of B. coagulans 
are available. Contrary to other LA producing bacteria, B. 
coagulans is not commonly considered as a part of the GIT 
microflora. Moreover, limited studies have been carried 
out to assess the ability of spore-forming probiotic Bacillus 
spp. to bond to the intestinal epithelium cells. Scientists 
have reported that B. coagulans is a transient 
microorganism because it is completely absent in fecal 
samples only within a few days after the end of 
consumption [61]. Ripamonti et al. [62] assessed adhesion 
of B. coagulans to a human embryonic intestine cell line. 
They showed that B. coagulans could adhere 
conspicuously to INT407 cells. Endres et al. [63] 
completely assessed safety of long oral consumption of B. 
coagulans (GanedenBC30
TM
), including in vitro and in 
vivo toxicology studies of mutagenicity assays, mouse 
micronucleus tests, chromosomal aberration assays, rabbit 
acute eye and skin irritation assays and acute oral toxicity 
tests in laboratory animals as well as 90-day sub-chronic 
oral toxicity tests in Wistar rats. Results of the 
toxicological safety studies showed that GanedenBC30
TM
 
did not include mutagenic, clastogenic or genotoxic 
effects. Concentrations of the probiotic biomass used in 




 since the 
suggested human daily dose included 100 × 10
6 




To further assess the safety of long-term B. coagulans 
consumption, a study was carried out in 2011 on one-year 
oral chronic toxicity of the bacteria combined with a single 
one-generation reproduction. Feeding B. coagulans 
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GanedenBC30™ to male and female Wistar rats revealed 
no symptoms of toxicity at the highest doses tested in 
parental generation and F1 offspring [64]. B. coagulans 
Unique IS-2 (MTCC-5260) is another spore-forming 
probiotic; for which, acute and sub-acute oral toxicity 
assessments were carried out in Sprague Dawley rats. 
Doses of 3250 and 6500 mg kg
-1
 body weight day
-1
 (5 × 
10
9
 B. coagulans Unique IS-2 spores g
-1
) were fed orally to 
the animals in acute toxicity assessment. Experimental 









) for 14 consecutive 
days in sub-acute toxicity assessment. Control animals 
received water alone. Half of the rats were sacrificed after 
14 and the remaining after 28 days of beginning of the 
experiment. The toxicity study indicated that clinical 
symptoms, clinical chemistry, body weight, food intake, 
urinalysis, hematological examinations, gross pathology 
and histopathology included no treatment-linked changes 
after 14 and 28 days. Based on the results of the study, B. 
coagulans Unique IS-2 strain could be considered as non-
pathogenic and safe for the human consumption [51]. 
7. Conclusion  
Various strains of B. coagulans are used as probiotics 
to improve and preserve ecological balances within the 
intestinal microflora. Although these probiotics are not 
native to human GIT, they can be used as beneficial 
bacteria; similar to other probiotic strains. In literatures, a 
limited number of reports on in vitro sub-chronic and 
chronic toxicity assessments, in vivo genotoxicity and 
human clinical trials are available. All of these studies 
approve safety of B. coagulans use at recommended doses. 
No enough information are available on how B. coagulans 
acts in medical applications. However, people consume 
these microorganisms to treat diseases such as diarrheas, 
IBS, inflammatory bowel disease, skin disorders, bacterial 
vaginoses and cancers. Appropriate doses of B. coagulans 
depend on several factors such as consumer age and health. 
In recent years, numerous clinical studies have been 
carried out on use of health promoting Bacillus spores in 
foods. Considering specific characteristics of spore-
forming probiotics, B. coagulans has demonstrated 
promising health potentials in probiotic food products. 
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  چکیده 
کوه  شوود، در حوالی به تحمل آنها در برابر عوامل استرس نسبت داده می های مفید رشد پروبیوتیک سابقه و هدف:
هوای هواگیای مهوم بوه عنوان گونهبهباسیلوس کواگوالنس، کوتاه و ناپایدار دارند.  ها عمر مفید نسبتاً اکثر پروبیوتیک
آور شرایط فراوری مواد غذایی ای به منظور کاهش اثرات زیانها، به طور فیاینده لحاظ اقتصادی، در زمینه پروبیوتیک
انود. ها و اطمینان از عملکرد آنها در بدن انسان مورد توجه قرار گرفتوه های باکتریمانی سلولو محیط زیست بر زنده
هدف از این مطالعه مروری، بررسی تحقیقات علمی انجام شوده روی ووواد درموانی، عملکوردی و ایمنوی زیسوتی 
 جدید بوده است.  یک پروبیوتیک عنوان به باسیلوس کواگوالنس
 های باسیلوس در مواد غذایی بوه کارگیری هاگمطالعات بسیاری در زمینه سالمت ترویج به گیری:و نتیجهها  یافته
هوای غیرهواگیا را دارنود و قوادر بوه  اغلب میایای سالمتی بخش پروبیوتیکباسیلوس کواگوالنس چاپ رسیده است. 
باشند. بوا توجوه بوه ای میروده-ایزای فراوری مواد غذایی و نیی شرایط مجرای معدهتحمل حرارت و شرایط استرس
  ای در تولید مواد غذایی پروبیوتیکپتانسیل امیدوارکننده باسیلوس کواگوالنسهای هاگیا،  مشخصات ویژه پروبیوتیک
 دهد.نشان می
  .ندارند مقاله این انتشار با مرتبط منافعی تعارض نوع هیچ که کنند می اعالم نویسندگان تعارض منافع: 
 واژگان کلیدی
 باسیلوس کواگوالنس ▪
 مواد غذایی فراسودمند ▪
  پروبیوتیک ▪
 ارزیابی ایمنی ▪
 تحمل تنش ▪
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